SCHEMBL4345936

SCHEMBL4345936

O=C(NCCc1ccccc1)Nc1cc(Br)cc(F)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
MAPT P10636 2/20 0.53
KMT2A Q03164 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
ALOX12 P18054 1/20 0.53
CYP2C19 P33261 1/20 0.53
RAB9A P51151 6/20 0.52
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA9 Q16790 2/20 0.51
TRPV1 Q8NER1 2/20 0.51
NPC1 O15118 6/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
CNR1 P21554 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4347712 0.87 RAB9A (0.60) MEN1MAPTKMT2ASMN1; SMN2RAB9A
SCHEMBL4346450 0.87 POLB (0.52) KMT2ASMN1; SMN2RAB9ACA12CA1
SCHEMBL4350090 0.85 SMN1; SMN2 (0.73) MEN1MAPTKMT2ASMN1; SMN2CYP1A2
SCHEMBL4351245 0.82 TRPV1 (0.58) MEN1MAPTKMT2ASMN1; SMN2CYP1A2
SCHEMBL4347762 0.80 NPC1 (0.59) MEN1MAPTKMT2ASMN1; SMN2RAB9A
SCHEMBL4350043 0.79 NPC1 (0.69) MEN1MAPTKMT2ASMN1; SMN2ALOX12
SCHEMBL27761084 0.78 EPHX2 (0.50) MAPTSMN1; SMN2RAB9ANPC1EPHX1
SCHEMBL4347794 0.77 EPHX2 (0.55) SMN1; SMN2RAB9ANPC1EPHX1POLB
SCHEMBL5594969 0.76 HTT (0.65) MEN1MAPTKMT2ASMN1; SMN2RAB9A
SCHEMBL4350095 0.76 MAPT (0.46) MEN1MAPTKMT2ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MEN1 2168/4885MAPT 4439/4885KMT2A 2096/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 MEN1 3901/4885MAPT 4184/4885KMT2A 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.